ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Icagen and Pfizer will collaborate to discover and develop compounds targeting three ion channels that are critical to the generation of electrical signals in nerve fibers that modulate pain. Pfizer will provide $38 million in funding during the first two years of the program, a figure that includes a $12 million up-front fee and a $15 million equity investment in Icagen. Icagen, based in Research Triangle Park, N.C., believes that "at least three unique products" could emerge from the pact.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter